Is Even The Pharma Industry Over COVID-19 Already?
Executive Summary
Data suggests fewer approvals and new product ideas, as the business case for new generic and brand treatments seems to be tougher to make now than at other times during the pandemic.
You may also be interested in...
CBER Staffing Remains Challenging, But Permanent Virtual Work May Help Offset Expected Retirements
Peter Marks predicts that staffing challenges within CBER can be alleviated by offering employees the flexibility to work remotely – permanently. With important posts in the vaccines office still to be hired, it could be an important incentive.
Thinking Post-COVID: How Will US FDA Transition Drug, Vaccine EUAs To Full Approvals?
Sponsors seek clarity about the transition process, which could last a year or longer.
Pfizer First: Oral Antiviral Paxlovid Wins EUA As Merck’s COVID Pill Languishes At US FDA
Authorized for mild-to-moderate COVID-19 in patients 12 and older at high risk for severe disease, Paxlovid (nirmatrelvir/ritonavir) jumped ahead of Merck & Co./Ridgeback’s molnupiravir in the EUA queue for oral antivirals, with the latter possibly hung up by efficacy and safety concerns.